Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2006
09/07/2006US20060199867 Ambroxol for the treatment of chronic pain
09/07/2006US20060199866 Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse
09/07/2006US20060199865 Synergistic combination comprising roflumilast and (r,r) - formoterol
09/07/2006US20060199864 Selection of pH-dependent compounds for in vivo therapy
09/07/2006US20060199863 Product containing prostaglandin
09/07/2006US20060199862 Method for enhancing cognitive function
09/07/2006US20060199861 Methods of using derivatives of (-)-venlafaxine
09/07/2006US20060199860 Salts of (-)-O-desmethylvenlafaxine
09/07/2006US20060199859 Topical medicaments and methods for photodynamic treatment of disease
09/07/2006US20060199858 Substituted benzopyrans as selective estrogen receptor-beta agonists
09/07/2006US20060199857 Therapeutic agents
09/07/2006US20060199856 Dihydroorotate dehydrogenase (DHODH) inhibitors; Rheumatoid arthritis, Pneumocystis carinii, fibrosis, uveitis, rhinitis, asthma, and athropathy; 2-(Biphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid
09/07/2006US20060199855 Process for producing atorvastatin hemicalcium
09/07/2006US20060199854 allows to recycle all solvents and the only by-products are inorganic salts; high overall yield and is suitable for industrial production
09/07/2006US20060199853 Analogs of 4-hydroxyisoleucine and uses thereof
09/07/2006US20060199852 Process for the preparation of substituted benzoxazole compounds
09/07/2006US20060199851 Novel compounds that are useful for improving pharmacokinetics
09/07/2006US20060199849 Solid lercanidipine free base
09/07/2006US20060199848 Ion channel modulating activity II
09/07/2006US20060199847 Stable ammonium salts of alpha-liponic acid, the production thereof and the use of the same
09/07/2006US20060199846 Certain substituted ureas as modulators of kinase activity
09/07/2006US20060199845 Thiophene compounds for inflammation and immune-related uses
09/07/2006US20060199844 Inhibitors of raf-kinase; Hyperproliferative disorders
09/07/2006US20060199843 Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
09/07/2006US20060199842 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
09/07/2006US20060199841 Pharmaceutical combination for the treatment of spasticity and/or pain
09/07/2006US20060199840 Chemical derivatives and their application as antitelomerase agent
09/07/2006US20060199839 minimal side effects, improved selectivity, potency, pharmacokinetics, and/or duration of action; 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[3-(4-methanesulfonylpiperazine-1-sulfonyl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; reduced motility of the gastrointestinal tract
09/07/2006US20060199838 3-hydroxy-N-(3-hydroxy-4-methoxyphenyl)-4-methoxybenzamide, used in the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyloidosis, such as observed non-insulin depepndent diabetes
09/07/2006US20060199837 Substituted tetrahydro-1h-pyrazolo [3,4-c]pyridines compositions comprising them, and use
09/07/2006US20060199836 Novel thienopyridine compounds, and methods of use thereof
09/07/2006US20060199835 Neuroprotective and anti-proliferative compounds
09/07/2006US20060199834 Prepared by dissolving 42-O-(2-hydroxy)ethyl-rapamycin in a solution containing an organic solvent and an aqueous buffer having a pH of 4 to 10; and extracting the SDZ-RAD Isomer C into an organic solvent; immunosuppressive, anti-inflammatory, antifungal, antiproliferative and antitumor agents
09/07/2006US20060199833 Novel chemiluminescent compounds and their use
09/07/2006US20060199832 Use of non-immunosupressive pipecolic acid derivatives for inducing chondrogenic differentiation
09/07/2006US20060199831 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
09/07/2006US20060199830 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds
09/07/2006US20060199829 Inhibitors of histone deacetylase
09/07/2006US20060199828 Pyrazine-2-carboxyamide derivatives
09/07/2006US20060199827 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
09/07/2006US20060199826 Cyclopropane compounds and pharmaceutical use thereof
09/07/2006US20060199825 4-Aminating a 4-chloro-2-hydroxy-3-nitrodihydroquinoline with a N-(hetero)cyclylpiperazine, and alkylating the remaining amine group in the quinoline ring to produce a 4-(4-(hetero)cyclylpiperazinyl)-3-nitro-1-alkyldihydroquinolinone
09/07/2006US20060199824 Treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis
09/07/2006US20060199823 Corticotropin releasing factor (CRF); affective disorders, anxiety disorders, stress-related disorders, eating disorders and substance abuse; eg 5-(1-Ethyl-propyl)-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine
09/07/2006US20060199822 Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
09/07/2006US20060199821 Heterocyclic amides and sulfonamides
09/07/2006US20060199820 e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma
09/07/2006US20060199819 Inhibition of cyclooxygenase-2 activity
09/07/2006US20060199818 Inhibiting the activity of a 5-hydroxytryptamine 2A by administering a N-heterocyclyl (preferably 1,3-dioxan-5-yl)-4-[(N-substituted)(hetero)arylamino]piperidine in which the N-substituant is arylalkanoyl, arylthioalkanoyl, arylalkylaminocarbonyl or arylalkylaminothiocarbonyl group
09/07/2006US20060199817 Phthalazine, aza- and diaza-phthalazine compounds and methods of use
09/07/2006US20060199816 Aryl sulfonyl piperidines
09/07/2006US20060199815 NK1 antagonists
09/07/2006US20060199814 Chemical Intermediate
09/07/2006US20060199813 Neurodegenerative diseases, psychological disorders; e.g. 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydroquinoline
09/07/2006US20060199812 Method of conjugating aminothiol containing molecules to vehicles
09/07/2006US20060199811 Contacting the liver tissue with taurolidine for inhibiting the development of metastases of a primary tumor to a tissue of a liver
09/07/2006US20060199810 Neurodegenerative diseases, psychological disorders; e.g. 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline
09/07/2006US20060199809 Factor Xa compounds
09/07/2006US20060199808 Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
09/07/2006US20060199807 Use of N-desmethylclozapine to treat human neuropsychia tric disease
09/07/2006US20060199806 10-[(2,2'-Dimethyl-1,1'-biphenyl-4-yl)carbonyl]-N-(3-methoxybenzyl)-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-3-carboxamide; antifertility agents
09/07/2006US20060199805 Combination therapy of flibanserin with another anxiolytic such as fluoxetine and buspirone
09/07/2006US20060199804 ATP-competitive inhibitors of serine/threonine kinase (mTOR); antifungal agents, anticancer agents, autoimmune diseases, inflammation, bone loss, bowel disorders, hepatic fibrosis/necrosis, rheumatoid arthritis, psoriasis
09/07/2006US20060199803 Compounds
09/07/2006US20060199802 Pyridyl derivatives and their use as therapeutic agents
09/07/2006US20060199801 Heterobicyclic compounds used as fungicides
09/07/2006US20060199799 Benzimidazolidinone derivatives as muscarinic agents
09/07/2006US20060199798 Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
09/07/2006US20060199797 Using compounds such as 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N {(R)- alpha -[N ((R)-1-carboxy-2-methylthio -ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine for therapy of Irritable Bowel Syndrome
09/07/2006US20060199796 Substituted benzofused heterocycles
09/07/2006US20060199795 e.g. 2-[3,5-trans-5-(3-aminophenyl)-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide; G-protein-coupled receptor (TGR5) agonist; central nervous system diseases; antiinflammatory agent; learning enhancement; angina pectoris, arrhythmia, bronchial asthma
09/07/2006US20060199794 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension
09/07/2006US20060199793 Sterol absorption inhibitor compounds
09/07/2006US20060199792 Peroxynitrite decomposition catalysts and methods of use thereof
09/07/2006US20060199791 Personal hygiene and hard surface cleaning agent; acne, skin complaints; effective against antibiotic resistant bacteria
09/07/2006US20060199790 Use of 3-methoxy-pregnenolone in the production of a medicament for treating neurodegenerative diseases
09/07/2006US20060199789 medical composition
09/07/2006US20060199788 Anti-inflammatory phosphonate compounds
09/07/2006US20060199787 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells
09/07/2006US20060199786 Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl) -1,3-oxathiolane or pharmaceutically acceptable salts thereof
09/07/2006US20060199785 Beta-cyclodextrin derivatives as antibacterial agents
09/07/2006US20060199784 Compound selected from sulfated cellulose and salts thereof and dermatitis therapeutic agent
09/07/2006US20060199783 Anti-Hepatitis c nucleosides containing 2-deoxy-2-fluoro-2-C-methyl- beta -D-ribofuranosyl nucleosides from a naturally-occurring nucleoside; Ethyl trans-2,3-dideoxy-4,5-O-isopropylidene-2-C-methyl-D-glycero-pent-2-enonate
09/07/2006US20060199782 Gene therapy using a SYN3 and SYN3 homolog delivery enhancing agent with an interferon protein or an interferon gene delivery system; anticarcinogenic agents
09/07/2006US20060199778 Methods and products related to non-viral transfection
09/07/2006US20060199776 7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-2H -chromen-2-one, for example; neuroprotective agents
09/07/2006US20060199775 Use of PKC-activating compounds as cardioprotectants and as apoptosis-inducing anti-tumor agents
09/07/2006US20060199774 Intensify nerve growth factor; using chroman compound
09/07/2006US20060199772 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
09/07/2006US20060199770 Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry
09/07/2006US20060199768 Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens
09/07/2006US20060199763 Derivatives of GLP-1 analogs
09/07/2006US20060199758 Prepared by reacting a cellulose, starch, or glycogen surface such as wood or cotton with a quaternary ammonium salt of 1,4-diazoniabicyclo [2.2.2]octane
09/07/2006US20060199229 Methods for identification of modulators of OSGPR116 activity, and their use in the treatment of disease
09/07/2006US20060199201 Targeted gene deletions for polysaccharide slime formers
09/07/2006US20060199179 Method for diagnosis of colorectal tumors
09/07/2006US20060198939 Porous ceramic composite bone grafts
09/07/2006US20060198914 Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders
09/07/2006US20060198906 Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
09/07/2006US20060198904 Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens